Journal: Neuron

Article Title: Enhancing oligodendrocyte myelination rescues synaptic loss and improves functional recovery after chronic hypoxia

doi: 10.1016/j.neuron.2018.07.017

Figure Lengend Snippet: (A) Experimental paradigm showing drug treatment and hypoxic exposure; (B, C) Representative images and quantification of MBP expression (red, B), CC1 positive OLs (green, C) in the brains and Caspr (red)/Nav1.6 (green) positive nodes (D) in the spinal cords of clemastine, (±)U50488 or vehicle treated mice. Error bars represent mean ± s.e.m. *p<0.05 or **p<0.01, significance based on Student’s t-test with the respective controls, n = 3 mice for each group. (E) Representative images and quantification of myelinated axons in the corpus callosum at P15. Error bars represent mean ± s.e.m. **p<0.01, significance based on Student’s t-test by comparing clemastine or (±)U50488 to vehicle, n = 3 mice for all experiments. Scale bar, 200μm (B), 100μm (C), 10μm (D) and 2μm (E). (F) The beam-walking test showing the frequency of foot slips of the clemastine, (±)U50488 or vehicle treated mice at P40, n = 7 mice for each group. *p<0.05, significance based on non-parametric Mann-Whitney test by comparing clemastine or (±)U50488 to vehicle; (G) The hypoxic mice treated with clemastine or (±)U50488 displayed significantly enhanced novel object recognition as compared to the vehicle controls, assessed 2 hours later after introduced to the objects, n = 7 mice for each group. *p<0.05, significance based on non-parametric Mann-Whitney test by comparing clemastine or (±)U50488 to vehicle. See also Figure S6–8.

Article Snippet: Drug treatment The hypoxic pups were treated with either clemastine (SelleckChem, Cat: S1847) or (±)U-50488 (Tocris, Cat: 0495) daily at 10mg/kg or the equivalent volume of vehicle by oral gavage from P3 to P10.

Techniques: Expressing, MANN-WHITNEY

Journal: Neuron

Article Title: Enhancing oligodendrocyte myelination rescues synaptic loss and improves functional recovery after chronic hypoxia

doi: 10.1016/j.neuron.2018.07.017

Figure Lengend Snippet: Key resources table

Article Snippet: Drug treatment The hypoxic pups were treated with either clemastine (SelleckChem, Cat: S1847) or (±)U-50488 (Tocris, Cat: 0495) daily at 10mg/kg or the equivalent volume of vehicle by oral gavage from P3 to P10.

Techniques: In Situ, Software

Journal: Experimental and therapeutic medicine

Article Title: Lidocaine protects H9c2 cells from hypoxia-induced injury through regulation of the MAPK/ERK/NF-κB signaling pathway.

doi: 10.3892/etm.2019.8055

Figure Lengend Snippet: Figure 1. Effect of lidocaine treatment on H9c2 cell damage induced by hypoxia. The release of (A) CK‑MB and (B) cTnI and (C) the mitochondrial survival rate were measured to determine the therapeutic effect of lidocaine on H9c2 cells under hypoxic conditions. The experimental data are presented as the mean ± SD of fold change compared to control and the data are from three independent experiments. **P<0.01 vs. Control; #P<0.05 and ##P<0.01 vs. Hypoxia. cTnI, cardiac troponin I; CK‑MB, creatine kinase‑muscle/brain.

Article Snippet: H9c2 cells were treated with lidocaine (0.5, 1, 5, 10 mM) for 48 h under hypoxic conditions before a rat cardiac troponin (cTnI) ELISA kit (cat. no. CSB-E08594r; Cusabio Technology LLC) and a rat creatine kinase-muscle/brain (CK-MB) ELISA kit (cat. no. CSB-E14403r; Cusabio Technology LLC) were used to evaluate cTnI and CK-MB release into the cell culture medium.

Techniques: Control

Journal: Experimental and therapeutic medicine

Article Title: Lidocaine protects H9c2 cells from hypoxia-induced injury through regulation of the MAPK/ERK/NF-κB signaling pathway.

doi: 10.3892/etm.2019.8055

Figure Lengend Snippet: Figure 4. Effect of lidocaine on the hypoxia‑induced inflammatory response of H9c2 cells. The concentrations of (A) IL‑1β, (B) TNF‑α and (C) IL‑6 were measured using ELISA kits. The mRNA levels of (D) IL‑1β, (E) TNF‑α and (F) IL‑6 were measured by reverse transcription‑quantitative PCR. Data are presented as the mean ± SD. **P<0.01 vs. Control; #P<0.05 and ##P<0.01 vs. Hypoxia. IL, interleukin; mRNA, microRNA; TNF‑α, tumor necrosis factor‑α.

Article Snippet: H9c2 cells were treated with lidocaine (0.5, 1, 5, 10 mM) for 48 h under hypoxic conditions before a rat cardiac troponin (cTnI) ELISA kit (cat. no. CSB-E08594r; Cusabio Technology LLC) and a rat creatine kinase-muscle/brain (CK-MB) ELISA kit (cat. no. CSB-E14403r; Cusabio Technology LLC) were used to evaluate cTnI and CK-MB release into the cell culture medium.

Techniques: Enzyme-linked Immunosorbent Assay, Control